Cosmos Health Projects $12M+ High-Margin Revenue from U.S. NOOR Collagen Expansion
COSM sits 16% above its 52-week low of $0.28.
Summary
Cosmos Health provided a significant corporate update, projecting over $12 million in additional high-margin annualized revenue from its U.S. expansion of NOOR Collagen products, with gross margins of approximately 75%. This new revenue projection is highly material, representing a substantial increase relative to the company's current market capitalization. The company also indicated it is evaluating options to address a perceived valuation disconnect, including potential monetization of its $18 million in non-core assets. While the update mentioned the previously announced Letter of Intent to acquire a Greek pharmacy distribution network for $11.5 million, the specific revenue guidance from the U.S. expansion is the primary new and actionable information for traders. Investors will now look for the updated guidance following the release of FY 2025 results and further R&D updates.
At the time of this announcement, COSM was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.2M. The 52-week trading range was $0.28 to $1.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.